We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
By Michael Dabaie
Vir Biotechnology Inc. shares were up 31.5% to $39.90 in morning trading.
Before the market open, Vir said research findings from the company's efforts to develop therapeutics for Covid-19 were published in the journal Nature.
The paper, entitled "Cross-neutralization of SARS-CoV and SARS-CoV2 by a human monoclonal antibody" details the identification and characterization of S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells.
Vir said it is advancing two clinical development candidates based on the S309 antibody as potential therapeutics for Covid-19, VIR-7831 and VIR-7832, in collaboration with GlaxoSmithKline PLC.
"Remarkably, we believe S309 likely covers the entire family of related coronaviruses, which suggests that, even as SARS-CoV-2 continues to evolve, it may be quite challenging for it to become resistant to the neutralizing activity of S309," said Herbert "Skip" Virgin, chief scientific officer of Vir.
Clinical testing is expected to begin this summer in collaboration with GSK, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 18, 2020 11:19 ET (15:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
